The IgM antibody is used in the production of the firm’s cell therapy, which is scheduled to enter a Phase I study in 2009 for transverse myelitis.
Goodwin Biotechnology (GBI) has begun process development and will be manufacturing a mAb used by Q Therapeutics in purifying its cell therapy, Q-Cells™. The IgM antibody recognizes a unique cell-surface marker that is expressed on Q-Cells (neural glial cells).
Q Therapeutics will use the mAb to manufacture Q-Cells. The company anticipates beginning Phase I trials for the treatment of transverse myelitis, a rapidly paralyzing subset of multiple sclerosis, in 2009.
